SCHEMBL3262162

SCHEMBL3262162

C=CCN(NC1CCCCC1)C(=O)CCN

nearest known ligand 0.35

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.35
GAA P10253 2/20 0.35
NPSR1 Q6W5P4 1/20 0.32
NPC1 O15118 4/20 0.32
SMN1; SMN2 Q16637 4/20 0.32
HTT P42858 1/20 0.32
RAB9A P51151 3/20 0.32
MAPT P10636 2/20 0.32
HPGD P15428 1/20 0.31
EPHX1 P07099 5/20 0.31
KDM4E B2RXH2 1/20 0.31
CYP3A4 P08684 1/20 0.31
EPHX2 P34913 1/20 0.31
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3261570 0.80 KMT2A (0.38) ALDH1A1SMN1; SMN2HPGDEPHX1KDM4E
SCHEMBL3259369 0.78 EPHX1 (0.37) ALDH1A1SMN1; SMN2EPHX1KDM4EEPHX2
SCHEMBL3263337 0.73 PKM (0.36) ALDH1A1NPSR1NPC1SMN1; SMN2RAB9A
SCHEMBL3261699 0.72 ALDH1A1 (0.35) ALDH1A1
SCHEMBL3259881 0.71 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2MAPT
SCHEMBL3259368 0.71 ALDH1A1 (0.34) ALDH1A1
SCHEMBL3261786 0.71 ALDH1A1 (0.32) ALDH1A1NPC1SMN1; SMN2RAB9AKDM4E
SCHEMBL4618237 0.70 ALDH1A1 (0.36) ALDH1A1MAPT
SCHEMBL3261043 0.70 EPHX1 (0.37) ALDH1A1NPC1SMN1; SMN2RAB9AEPHX1
SCHEMBL3263457 0.70 ADH1C (0.35) ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937090-B2 Parakeratosis inhibitor, pore-shrinking agent and external composition for skin SHISEIDO COMPANY, LTD. (JP) 2015-01-20 US disclosed
US-20120232111-A1 Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin SHISEIDO COMPANY, LTD. (JP) 2012-09-13 US disclosed
US-20120165409-A1 WRINKLE-IMPROVING AGENT SHISEIDO COMPANY, LTD. (JP) 2012-06-28 US disclosed
US-20100035881-A1 WRINKLE-IMPROVING AGENT SHISEIDO COMPANY, LTD. (JP) 2010-02-11 US disclosed
EP-1941861-A1 WRINKLE-IMPROVING AGENT Shiseido Company, Limited (JP) 2008-07-09 EP disclosed
EP-1880711-A1 PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN Shiseido Company, Limited (JP) 2008-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035881-A1 WRINKLE-IMPROVING AGENT AAAS, GLA, COL14A1 ALDH1A1 1501/4885GAA 43/4885NPSR1 2216/4885
US-20120232111-A1 Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin CUTA, AAAS, NUP160 ALDH1A1 3543/4885GAA 486/4885NPSR1 4560/4885
US-20120165409-A1 WRINKLE-IMPROVING AGENT AAAS, GLA, COL14A1 ALDH1A1 1151/4885GAA 40/4885NPSR1 2485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.